Death from metastatic donor-derived ovarian cancer in a male kidney transplant recipient.
Posttransplant malignancy developing in an allograft is an uncommon complication of organ transplantation. The tumor may represent malignant transformation of donor or recipient cells that were previously normal, metastatic malignancy of recipient origin or malignancy transmitted from organ donor to recipient. Establishing the origin of the malignancy is critical to treatment algorithms. It is generally believed allograft removal and immunosuppression withdrawal will lead to resolution of transmitted malignancies in cases where the renal allograft is the origin. We report a male patient who developed metastatic ovarian malignancy secondary to donor transmission.
Lipshutz
G S
GS
Department of Surgery and Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. glipshutz@mednet.ucla.edu
Mihara
N
N
Wong
R
R
Wallace
W D
WD
Allen-Auerbach
M
M
Dorigo
O
O
Rao
P N
PN
Pham
P-C T
PC
Pham
P-T T
PT
D002288:Adenocarcinoma, Mucinous / Q000209:etiology* / Q000556:secondary; D000328:Adult; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000209:etiology* / Q000556:secondary; D016030:Kidney Transplantation / Q000009:adverse effects*; D008113:Liver Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D010051:Ovarian Neoplasms / Q000209:etiology* / Q000473:pathology; D014019:Tissue Donors; D014057:Tomography, X-Ray Computed